Omeros Corporation OMER

Updated: 19 Jun 2026

NASDAQ | Biotech | Biopharmaceuticals

No signal published yet

We already track Omeros and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Omeros free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biopharmaceuticals
We're already tracking Omeros Corporation — here are the latest events we've registered

Recent News

  • On June 18, 2026, Omeros announced agreements to repurchase up to $16 million in principal amount of its 2029 convertible notes for approximately $34 million. The final purchase price is subject to adjustment based on the trading price of the company's common stock during a specified averaging period.

What Firelda Watch includes for Omeros Corporation

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Omeros Corporation will be delivered in the same format.

Want to follow Omeros Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Omeros free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Omeros Corporation OMER
Omeros — follow and we'll monitor it
Follow Omeros free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.